QUÉBEC, QC — February 2, 2026 — Leads & Copy — Devonian Health Group Inc. has appointed Dennis Turpin as Chief Financial Officer, effective today.
Turpin, who currently serves on the Board of Directors, will remain in that role. Before being appointed CFO, he was Chair of the Audit Committee, a role that will now be assumed by Pierre Labbé.
Dr. André P. Boulet, PhD, Chief Executive Officer, said he is pleased to welcome Turpin, and is confident that he will help strengthen the company’s management approach, diversify perspectives, enhance expertise, and help guide the development of Devonian.
Turpin is a seasoned professional executive and chartered professional accountant with significant experience in finance, capital markets transactions, business development, as well as mergers and acquisitions, with over 25 years in the biopharmaceutical industry.
Turpin will replace Viktoria Krasteva, who will remain with the company to assist with the transition until February 27, 2026. The Board thanked Krasteva for her contributions and wished her well.
The company granted Turpin 25,000 stock options, vesting immediately and exercisable at a price of $11.50 for a period of 10 years.
The company also corrected a press release issued on December 19, 2025, regarding the granting of 2,948,056 stock options to directors and a consultant, 385,950 to employees, and 100,000 to a research and development consultant. The exercise price of stock options may not be set below the market price of the common shares at the close of trading on the exchange on the trading day immediately preceding the grant date. Accordingly, the exercise price was corrected from $0.18 to $0.19, the applicable market price.
All other terms of the stock option grants remain unchanged. Further to the share consolidation completed on January 22, 2026, on the basis of one post-consolidation common share for every 60 pre-consolidation common shares, the stock options have been automatically adjusted. Each block of 60 pre-consolidation options now represents one post-consolidation option, and the corrected exercise price of $0.19 per share has been adjusted to $11.40 per share on a post-consolidation basis. The number of options has been rounded down to allow the holder to purchase only a whole number of common shares upon exercise.
Devonian Health Group Inc., incorporated in 2015 and headquartered in Quebec, Canada, is a clinical stage pharmaceutical company specializing in the development of drugs for various auto-immune fibroinflammatory diseases with novel therapeutic approaches to targeting unmet medical needs. The company develops prescription drugs for the treatment of fibroinflammatory autoimmune diseases including atopic dermatitis, radiodermatitis and ulcerative colitis.
Devonian also develops cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings and owns a commercialization subsidiary, Altius Healthcare LP, focused on selling prescription pharmaceutical products in Canada, under licenses from brand name pharmaceutical companies. Devonian owns a state-of-the art extraction facility.
Devonian is traded publicly on the TSX Venture Exchange (TSXV: GSD) and quoted on the OTCQB Venture Market (OTCQB: DVHGF).
Source: Devonian Health Group Inc.
